In the last trading session, 6.62 million Humacyte Inc (NASDAQ:HUMA) shares changed hands as the company’s beta touched 2.00. With the company’s per share price at $2.59 changed hands at -$0.03 or -1.15% during last session, the market valuation stood at $401.76M. HUMA’s last price was a discount, traded about -277.99% off its 52-week high of $9.79. The share price had its 52-week low at $1.15, which suggests the last value was 55.6% up since then.
Analysts gave the Humacyte Inc (HUMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HUMA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Humacyte Inc’s EPS for the current quarter is expected to be -0.18.
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA was in red as seen at the end of in last trading. With action -3.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -48.71%, with the 5-day performance at -3.00% in the red. However, in the 30-day time frame, Humacyte Inc (NASDAQ:HUMA) is 112.30% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 56.83% from its current market value. According to analyst projections, HUMA’s forecast low is 5 with 10 as the target high. To hit the forecast high, the stock’s price needs a -286.1% plunge from its current level, while the stock would need to soar -93.05% for it to hit the projected low.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 935.86k. 7 analysts are of the opinion that Humacyte Inc’s revenue for the current quarter will be 2.34M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 42.43%. The 2025 estimates are for Humacyte Inc earnings to increase by 80.49%.
HUMA Dividends
Humacyte Inc is expected to release its next quarterly earnings report in July.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 3.9686% or 4.73 million shares worth $22.7 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 3.81 shares estimated at $9.87 million under it, the former controlled 2.63% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.64% of the shares, roughly 2.37 shares worth around $6.15 million.
